GLIOBLASTOMA: IMPACT OF MOLECULAR GENETIC DIAGNOSTICS AFTER SURGICAL TREATMENT ON SURVIVAL PROGNOSIS.

Abstract

This study aimed to evaluate the impact of molecular genetic markers on overall survival (OS) and progression-free survival (PFS) in patients with glioblastoma following surgical treatment. A retrospective-prospective study included 220 patients who underwent surgery between January 2022 and May 2026. Molecular genetic analysis assessed IDH1/IDH2 mutations, MGMT promoter methylation, TERT promoter mutations, and EGFR amplification. Survival outcomes were evaluated using the Kaplan–Meier method, log-rank test, and multivariable Cox regression analysis. The results demonstrated that MGMT promoter methylation and IDH mutations were associated with longer OS and PFS. Patients with methylated MGMT and IDHmutant tumors showed more favorable survival outcomes. Conversely, TERT promoter mutations and EGFR amplification were associated with shorter survival. Younger age and gross total tumor resection were also identified as favorable prognostic factors. These findings highlight the importance of integrating molecular genetic diagnostics with clinical and surgical data to improve prognostic assessment, personalize treatment strategies, and optimize postoperative management in patients with glioblastoma.